Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Investor Presentation (April 2023)
34 slides from Arovella Therapeutics's investor presentation, Apr 4, 2023
Slide 1: Arovella iNKT Cell Platform Explanatory Webinar Presentation
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release For personal use only 4 April 2023 AROVELLA iNKT CELL PLATFORM EXPLANATORY WEBINAR PRESENTATION • Explanatory webinar to be held 11AM AEST today • Describing cell therapy and iNKT cell basics and the advantages of Arovella’s CAR-iNKT
Slide 2: ALA-101: An Allogeneic iNKT Cell Cancer Therapy
For personal use only ASX:ALA ALA-101: An Allogeneic iNKT Cell Cancer Therapy Explanatory Webinar 4 April 2023
Slide 3: CEO & Managing Director Dr. Michael Baker
For personal use only CEO & MANAGING DIRECTOR Dr. Michael Baker © Copyright Arovella Therapeutics Ltd 2023
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). For pers
Slide 5: Arovella Therapeutics Highlights
Arovella Therapeutics Highlights For personal use only Allogeneic iNKT Cell Platform World Leading Partners Strong Leadership Group Arovella is developing off-the-shelf invariant Arovella’s technologies are licensed from Arovella’s leadership team and its Board Natural Killer T (iNKT) cell therapies
Slide 6: What are CAR-T Cells?
What are “CAR-T Cells”? For personal use only T cells are a common type of immune cell that fight infections and can help fight cancer To generate autologous CAR-T cells, T cells are taken from a patient with blood cancer and ‘reprogrammed’ to produce a Chimeric Antigen Receptor (CAR) o The CAR
Slide 7: Cell Therapy Has Revolutionized Blood Cancer Treatment
Cell Therapy Has Revolutionized Blood Cancer Treatment CAR-T cells have demonstrated ability to cure haematological cancers and have generated strong sales For personal use only The Cell Therapy market is expected to reach $12.3 billion by 20301 February 2022 May 2022 Product Approval 2022 Year
Slide 8: But…Manufacturing and Logistics Pose Major Challenges
But…Manufacturing and Logistics Pose Major Challenges For personal use only T cells must originate from the patient to be treated so each manufacturing batch is patient-specific Arovella’s allogeneic CAR-iNKT cell High manufacturing and supply chain costs lead to high drug platform has the poten
Slide 9: Advantages of iNKT Cells
Advantages of iNKT Cells Cells from a healthy donor can be used to For personal use only treat patients (no GvHD) Modify the tumour microenvironment and Naturally target tumour cells through iNKT cells kill cells that promote tumour growth subpopulation of T cells invariant TCR (CD1d); dual targetin
Slide 10: The Potential of CAR-iNKT Cells is Untapped
The Potential of CAR-iNKT Cells is Untapped For personal use only 9 © Copyright Arovella Therapeutics Ltd 2023
Slide 11: Senior VP Development & Translational Medicine Dr. Mini Bharathan
For personal use only SENIOR VP DEVELOPMENT & TRANSLATIONAL MEDICINE Dr. Mini Bharathan © Copyright Arovella Therapeutics Ltd 2023
Slide 12: Natural Level of iNKT Cells Correlates With Patient Survival
Natural Level of iNKT Cells Correlates With Patient Survival For personal use only High levels of natural circulating iNKT cells correlate High natural levels of iNKT cells within colorectal with improved survival outcomes for patients with tumours correlated with improved survival head and neck
Slide 13: CAR-iNKT Cell Therapy Production Advantages
CAR-iNKT Cell Therapy Production Advantages Manufacturing For personal use only Collect Healthy Isolate iNKT cells Engineer iNKT cells to Expand to grow billions of Vial and freeze Donor Blood produce a CAR CAR-iNKT cells CAR-iNKT cells Treatment Thaw CAR-iNKT cells Allogeneic Manufacturing Advantag
Slide 14: CAR19-iNKT (ALA-101) Cells Can Be Expanded
CAR19-iNKT (ALA-101) Cells Can Be Expanded For personal use only Collect Healthy Isolate iNKT cells Engineer iNKT cells to Expand to grow billions of Donor Blood produce a CD19 CAR CAR19-iNKT cells Fold increase in cell number Arovella selects healthy donor-derived iNKT cells with a phenotype to m
Slide 15: CAR-iNKT Cells Mechanism of Action
CAR-iNKT Cells Mechanism of Action For personal use only TAM = Tumour Associated Macrophage; MDSC = Myeloid Derived Suppressor Cell; CAR = Chimeric Antigen Receptor; NK = Natural Killer 14 © Copyright Arovella Therapeutics Ltd 2023
Slide 16: CAR-iNKT Platform Can Be Used for a Variety of CARs
CAR-iNKT Platform Can Be Used for a Variety of CARs CD19-CAR CAR targeting For personal use only different protein on cancer cells CAR-T CAR-iNKT 15 © Copyright Arovella Therapeutics Ltd 2023
Slide 17: CAR19-iNKT Cells (ALA-101) are Dual Targeting
CAR19-iNKT Cells (ALA-101) are Dual Targeting Cytotoxic activity of CAR19-iNKT cells For personal use only CD19 is an antigen expressed on normal B cells and malignant against K562 cells expressing ±CD1d/±CD19 B cells of leukemias and lymphomas o CD19-targeting CAR T-cells is a proven therapeutic
Slide 18: CAR-iNKT Cells (ALA-101) Kill Patient-Derived Primary Tumour Cells
CAR-iNKT Cells (ALA-101)Kill Patient-Derived Primary Tumour Cells Mantle cell lymphoma For personal use only Patient 1 Patient 2 CAR19-iNKT cells kill CD19-expressing lymphoma cells more effectively than CAR T cells o Tested against tumour cells from multiple Cytotoxic activity (%) patients using
Slide 19: CAR-iNKT Cells (ALA-101) Display Enhanced Tumour Killing In Vivo
CAR-iNKT Cells (ALA-101) Display Enhanced Tumour Killing In Vivo For personal use only CAR19-iNKT cells were assessed in a mouse tumour model Tumour cells expressing CD19 and CD1d were intravenously delivered into mice Tumour cells are tagged with luciferase so that they can be measured within l
Slide 20: CAR-iNKT Cells (ALA-101) Display Enhanced Tumour Killing In Vivo
CAR-iNKT Cells (ALA-01)Display Enhanced Tumour Killing In Vivo For personal use only CAR19-iNKT cells rapidly clear tumour PBS T iNKT CAR19-T ALA-101 cells in mice Mice were treated with: Ventral PBS (saline) Day 0 Unmodified T cells (T) Unmodified iNKT cells (iNKT) Dorsal CAR19-T cells
Slide 21: CAR-iNKT Cells (ALA-101): Superior Animal Survival Over CAR T-Cells
CAR-iNKT Cells (ALA-101): Superior Animal Survival Over CAR T-Cells For personal use only CAR19-iNKT cells significantly increased survival in mice versus CAR19-T cells After 90 days, only mice treated with CAR19-T cells or CAR19-iNKT cells remained alive 1.5x more mice treated with CAR19-iNKT c
Slide 22: CAR-iNKT Cells: Spontaneous Secondary Remission
CAR-iNKT Cells: Spontaneous Secondary Remission For personal use only CAR-iNKT activity may persist to eradicate tumour cells following relapse Ventral Four mice treated with CAR-iNKT cells had the cancer return to the brain Dorsal In all four mice, tumour cells were eliminated a second time wit
Slide 23: Arovella's iNKT Cell Platform Has Several Advantages
Arovella’s iNKT Cell Platform Has Several Advantages Uses mature iNKT cells from healthy adult donors and does not require For personal use only ‘reprogramming’ of stem cells High ‘transduction efficiency’, a high percentage of isolated iNKT cells (>60%) become modified to express the CAR Transducti
Slide 24: Arovella Has a Unique, Proprietary Manufacturing Process
Arovella Has a Unique, Proprietary Manufacturing Process Developed at Imperial College London by Professor Tassos For personal use only Karadimitris Exclusive worldwide licence granted to Arovella in 2021 Patent granted in Europe and pending in United States, Canada, China, Hong Kong and Austral
Slide 25: ALA-101 Scale-Up and Preparation for Clinical Material
ALA-101 Scale-Up and Preparation for Clinical Material For personal use only Complete ALA-101 is Arovella’s lead product, a Optimised viral vector to engineer the CAR CD19-targeting CAR-iNKT cell therapy with regulatory-friendly elements On track Identify high-frequency iNKT cell donors Ongoing
Slide 26: Combining ALA-101 and CF33-CD19 (onCARlytics)
Combining ALA-101 and CF33-CD19 (onCARlytics) For personal use only ALA-101 is very potent and is rapidly CF33 is an oncolytic virus that targets activated to kill CD19 expressing cancers1 tumour cells being developed by Imugene2 The product is being developed as an off- CF33 has been engine
Slide 27: ALA-101 + onCARlytics Mechanism of Action
ALA-101 + onCARlytics Mechanism of Action For personal use only Research collaboration progressed to in vivo testing based on promising in vitro results 26 © Copyright Arovella Therapeutics Ltd 2023
Slide 28: Arovella's Potential Cancer Targets
Arovella’s Potential Cancer Targets CD19-CAR CD19-CAR DKK1-CAR For personal use only ALA-101 ALA-101 + onCARlytics ALA-104 Non-Hodgkin’s Head and Neck Prostate Cancer Brain Triple Negative Pancreatic Lung Cancer Multiple Lymphoma Cancer Metastases Breast Cancer Cancer Myeloma Additional CARs can b
Slide 29: Arovella's Key Milestones Over Months
Arovella’s Key Milestones Over 18 Months Cell Therapy For personal use only Partner Discovery Lead Optimisation IND-Enabling Phase 1 CAR19-iNKT CD19 Expressing Lymphoma (ALA-101) ALA-101 + Solid Tumours onCARlytics Multiple Myeloma TNBC DKK1-CAR-iNKT (ALA-104) NSCLC Pancreatic TNBC – triple negative
Slide 30: Arovella Has a Strong Leadership Team
Arovella Has a Strong Leadership Team LEADERSHIP For personal use only Dr. Michael Baker Dr. Nicole van der Weerden Dr. Mini Bharathan Dr. Robson Dossa Ana Radeljevic CEO & MANAGING DIRECTOR CHIEF OPERATING OFFICER SENIOR VP DEVELOPMENT & SENIOR DIRECTOR BUSINESS DEVELOPMENT TRANSLATIONAL MEDICINE M
Slide 31: Recent Cell Therapy Transactions
Recent Cell Therapy Transactions For personal use only Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Stage Upfront ($M) ($M) value Jan-23 Acquisition Phase I $200 $120 $320 Development Oct-22 Phase II $225* undisclosed collaboration Research Sep-22 Preclincal $70 undisclo
Slide 32: Arovella Financial Overview
Arovella Financial Overview Financial Snapshot 14,000,000 For personal use only ALA Price and Volume - 12 Months1 ASX CODE ALA $0.05 12,000,000 Market capitalisation1 $36.2 million Shares on issue 755.5 million 10,000,000 $0.04 52-week low / high $0.020 / $0.048 8,000,000 Cash (30 December 2022)2 $5
Slide 33: Thank You
For personal use only Thank You Email: investor@arovella.com © Copyright Arovella Therapeutics Ltd 2023
Slide 34: Notes to Editors: About Arovella Therapeutics Ltd
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd For personal use only Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing therapies to treat human diseases. Arovella is developing its invariant natural killer
Arovella Therapeutics — Investor Presentation (April 2023) on 6ix